BETA · In development—Rankings and features improve every week.Spotted an error?Tell us →
Sign in / Register

Thriva

ActiveOn the In-vitro diagnostics Radar · not ranked

In-vitro diagnostics · United Kingdom

At-home blood testing service that sends finger-prick kits, analyses samples in partner labs and gives consumers and employers personalised health reports and tracking.

HQUnited Kingdom
Last roundSeries A (extension) · May 2020

Why Thriva is not ranked yet

How the Radar works →

The Radar lists every known eligible company, sorted by date of last round, with no AI judgement. Thriva enters the ranking once its public data is sufficient for the AI to estimate it. Next In-vitro diagnostics worldwide edition: 12 Apr 2027.

Funding history

DateRoundAmountTypeInvestors
May 2020Series A (extension)—EquityTarget Global, Guinness Asset Management, Pembroke VCT

Rounds as cited by Uback’s rankings. Equity, debt and grants are shown separately; only equity rounds count towards the valuation anchor.

Uback rankings

How the AI ranks →
RankingTierRankEditionNext update
In-vitro diagnostics · worldwideRadar—Edition 0 · Oct 202612 Apr 2027

Independent analyses

By industry professionals & analysts

Industry professionals and financial analysts can publish their own analysis of Thriva as a PDF. It must answer at least one of these four questions, and stick to them:

ValuationWhat is Thriva worth?
Versus competitorsHow does it compare?
Who should acquire itStrategic buyers, and why
Who should it acquireAcquisition targets, and why
Publish an analysisName, role and LinkedIn shown · public sources only

Analyses are the opinion of their authors, not of Uback. They are checked before publication.

Comparable companies in in-vitro diagnostics

Full in-vitro diagnostics ranking →

Last updated: Oct 2026Report an error

Uback is a content publisher and an aggregator of non-binding expressions of interest. It provides no investment advice, receives no mandate and takes part in no transaction. Rankings, ranges and brackets are editorial estimates produced by AI, purely indicative.